OUR PRESS RELEASES AND NEWS UPDATES
These press releases and news updates are intended for media and investors only
Showing results for
-
ViiV Healthcare announces label update for its long-acting HIV treatment, Cabenuva (cabotegravir, rilpivirine), to be initiated with or without an oral lead-in period
24 Mar 2022ViiV Healthcare announces label update for its long-acting HIV treatment, Cabenuva (cabotegravir, rilpivirine), to be initiated with or without an oral lead-in period -
ViiV Healthcare shares new data from Positive Perspectives, Wave 2 study, confirming a more holistic approach to HIV care can improve quality of life
04 Jul 2020High levels of engagement between healthcare providers and people living with HIV are associated with better health outcomes -
March
14 Mar 2019 -
ViiV Healthcare receives CHMP Positive Opinion for Tivicay EU label update with GEMINI study data for the 2-drug regimen of Tivicay + lamivudine (1)
16 Nov 2018CHMP Positive Opinion received for Tivicay EU label update with GEMINI study data for the 2-drug regimen of Tivicay + lamivudine -
ViiV Healthcare reports positive 48-week results for second phase III study for novel, long-acting, injectable HIV-treatment regimen
30 Oct 2018FLAIR study meets primary endpoint, showing similar efficacy of a once-a-month, investigational, injectable two-drug regimen of cabotegravir and rilpivirine compared to a daily, oral three-drug, integrase-based regimen in virally-suppressed adults. -
ViiV Healthcare submits New Drug Application to US FDA for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV
18 Oct 2018ViiV Healthcare submits New Drug Application to US FDA for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV -
ViiV Healthcare update on how we work with healthcare professionals
02 Oct 2018ViiV Healthcare update on how we work with healthcare professionals -
ViiV healthcare submits regulatory application to EMA for single tablet two drug regimen of dolutegravir and lamivudine for treatment of hiv
14 Sep 2018ViiV Healthcare submits regulatory application to European Medicines Agency for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV -
ViiV Healthcare announces SWORD 100-week data for Juluca (dolutegravir/rilpivirine) at AIDS 2018
24 Jul 2018100-week results from the SWORD phase III programme evaluating the safety and efficacy of switching virologically suppressed patients from a three or four-drug antiretroviral regimen to a 2-drug regimen of dolutegravir. and rilpivirine. -
ViiV Healthcare presents phase III data showing two drug regimen has similar efficacy to a three-drug regimen in treatment naïve HIV patients, with no resistance
24 Jul 2018GEMINI 1 & 2 studies meet primary endpoint, showing two-drug regimen to be effective across high and low viral loads -
ViiV Healthcare receives EU marketing authorisation for Juluca (dolutegravir/rilpivirine), the first 2-drug regimen, once-daily, single-pill for the treatment of HIV
21 May 2018Juluca maintains viral suppression with two drugs in the smallest single pill regimen -
ViiV Healthcare gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe
23 Mar 2018Committee for Medicinal Products for Human Use (CHMP) has issued a Positive Opinion for Juluca -
ViiV Healthcare announces positive new dolutegravir data for the treatment of people living with HIV co-infected with tuberculosis
05 Mar 2018INSPIRING study results contribute to the extensive body of evidence for dolutegravir, the leading integrase strand transfer inhibitor, in diverse and hard to treat patient populations -
ViiV Healthcare launches eighth phase III study in two-drug regimen programme for HIV-1 treatment
08 Feb 2018TANGO study will investigate dolutegravir (TIVICAY) and lamivudine (EPIVIR) in patients with HIV who have achieved viral suppression on a tenofovir alafenamide fumarate-based regimen -
ViiV Healthcare announces start of phase III study of long-acting cabotegravir for HIV prevention in women
30 Nov 2017The HPTN 084 study will evaluate injections given every two months -
ViiV Healthcare announces US FDA approval for Juluca®
21 Nov 2017Juluca® (dolutegravir and rilpivirine) approved in US as first 2-drug regimen, once-daily, single pill - a complete regimen for the maintenance treatment of virologically suppressed HIV-1 infection -
ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV
27 Oct 2017ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV -
Tivicay® and Celsentri® now included in the Essential Drug List in Russia
24 Oct 2017Both medicines expected to be available in HIV specialist treatment centres from 2018 onwards -
ViiV Healthcare and NEAT-ID announce results from the NEAT 022 study at the International AIDS Society meeting in Paris
25 Jul 2017Collaborative study of dolutegravir treatment in patients with HIV and high CV risk -
ViiV Healthcare announces superior efficacy of dolutegravir versus lopinavir/ritonavir in second-line HIV treatment in resource-limited settings
25 Jul 2017Results of DAWNING to find efficacy of DTG versus LPV/RTV plus 2 NRTIs in second-line treatment announced -
Phase II study results showed comparable viral suppression rates at 96 weeks for a two-drug regimen
24 Jul 2017Comparable viral suppression rates at 96 weeks for a two drug regimen of long acting dolutegravir and rilpivirine and a three drug regimen in patients with HIV -
ViiV Healthcare shares data from its innovative portfolio with HIV community at IAS 2017
20 Jul 2017Press release for HIV research presented at IAS 2017 -
ViiV Healthcare’s Positive Action Europe Programme awards grants to 14 community-based organisations
14 Jun 2017Positive Action Europe fourth grant cycle comes to a close as 14 patient advocacy organisations across Europe have been awarded grants to deliver education, support services and care for people living with HIV -
ViiV Healthcare submits regulatory applications for the first HIV maintenance regimen comprising only two medicines
01 Jun 2017First regulatory submissions for two drug HIV treatment regimen -
Honoring the memory of Dr Mark Wainberg
13 Apr 2017 -
ViiV Healthcare joins PENTA Foundation in search for strategies to achieve remission in children living with HIV
29 Jun 2016ViiV Healthcare joins PENTA Foundation in search for strategies to achieve remission in children living with HIV -
ViiV Healthcare announces FDA approval to lower the weight limit for dolutegravir in children and adolescents living with HIV
10 Jun 2016ViiV Healthcare announces FDA approval to lower the weight limit for dolutegravir in children and adolescents living with HIV -
ViiV Healthcare announces public tender agreement with Botswana Ministry of Health for dolutegravir
03 Jun 2016ViiV Healthcare announces public tender agreement with Botswana Ministry of Health for dolutegravir -
ViiV Healthcare and the International Association of Providers of AIDS Care to Collaborate on Fast-Track Cities
31 May 2016ViiV Healthcare and the International Association of Providers of AIDS Care to Collaborate on Fast-Track Cities -
ViiV Healthcare extends Medicines Patent Pool licence agreement for dolutegravir to cover all lower middle-income countries
25 Apr 2016ViiV Healthcare extends Medicines Patent Pool licence agreement for dolutegravir to cover all lower middle-income countries -
Global partnership launches new programme with goal to save the lives of thousands of children affected by HIV in Lesotho
08 Apr 2016Global partnership launches new programme with goal to save the lives of thousands of children affected by HIV in Lesotho -
ViiV Healthcare announces first phase II HIV prevention study results for investigational long-acting injectable cabotegravir
24 Feb 2016ViiV Healthcare announces public tender agreement with Botswana Ministry of Health for dolutegravir -
ViiV Healthcare announces phase II study results for first two drug, long-acting injectable regimen for HIV-1 treatment
23 Feb 2016ViiV Healthcare announces phase II study results for first two drug, long-acting injectable regimen for HIV-1 treatment -
ViiV Healthcare to acquire Bristol-Myers Squibb HIV R&D assets
18 Dec 2015Two transactions strengthen ViiV Healthcare’s position at the forefront of HIV innovation -
ViiV Healthcare highlights its continued commitment to end mother to child transmission of HIV
30 Nov 2015ViiV Healthcare highlights its continued commitment to end mother to child transmission of HIV -
ViiV Healthcare at ICASA: Improving Access to HIV Treatment and Care for People Everywhere
29 Nov 2015ViiV Healthcare at ICASA: Improving Access to HIV Treatment and Care for People Everywhere -
ViiV Healthcare gets ready for Africa’s largest HIV-AIDS Conference
27 Nov 2015ViiV Healthcare gets ready for Africa’s largest HIV-AIDS Conference -
ViiV Healthcare Awards Additional Round of Grants to Support Innovative HIV Programs Aimed at Reducing Disparities in the Southern US
20 Nov 2015ViiV Healthcare Awards Additional Round of Grants to Support Innovative HIV Programs Aimed at Reducing Disparities in the Southern US -
ViiV Healthcare announces positive headline results from a study of two drug injectable regimen for HIV maintenance therapy
03 Nov 2015ViiV Healthcare announces positive headline results from a study of two drug injectable regimen for HIV maintenance therapy -
ViiV Healthcare awards 23 small grants to help alleviate the stigma of HIV and AIDS in the MSM and transgender community globally
26 Oct 2015ViiV Healthcare awards 23 small grants to help alleviate the stigma of HIV and AIDS in the MSM and transgender community globally -
ViiV Healthcare employee named top marketer in healthcare industry, by Medical Marketing & Media
13 Oct 2015ViiV Healthcare employee named top marketer in healthcare industry, by Medical Marketing & Media -
New Phase IIIb/IV data show switching to once-daily Triumeq® maintains HIV viral suppression
23 Sep 2015New Phase IIIb/IV data show switching to once-daily Triumeq® maintains HIV viral suppression -
ViiV Healthcare and Desano Pharmaceuticals’ manufacturing agreement will allow competitive supply of dolutegravir in China and several developing countries
02 Jul 2015ViiV Healthcare and Desano Pharmaceuticals’ manufacturing agreement will allow competitive supply of dolutegravir in China and several developing countries -
ViiV Healthcare Announces New Positive Action Project in US for MSM Youth, Calls for Proposals
22 Jun 2015ViiV Healthcare Announces New Positive Action Project in US for MSM Youth, Calls for Proposals -
ViiV Healthcare and CHAI collaboration delivers second milestone with first filing with the FDA of generic dolutegravir by Aurobindo Pharma for the treatment of HIV
26 May 2015ViiV Healthcare and CHAI collaboration delivers second milestone with first filing with the FDA of generic dolutegravir by Aurobindo Pharma for the treatment of HIV -
European Patient Advocacy Groups Awarded Grants from Positive Action Europe
13 May 2015European Patient Advocacy Groups Awarded Grants from Positive Action Europe -
ViiV Healthcare begins phase III programme with dolutegravir/rilpivirine combination for HIV maintenance therapy
06 May 2015ViiV Healthcare begins phase III programme with dolutegravir/rilpivirine combination for HIV maintenance therapy -
ViiV Healthcare Launches New Global Positive Action Programme Focused on MSM and Transgender Populations
31 Mar 2015ViiV Healthcare Launches New Global Positive Action Programme Focused on MSM and Transgender Populations -
ViiV Healthcare announces the approval in Japan of Triumeq® (dolutegravir, abacavir and lamivudine), a new single-pill regimen for the treatment of HIV infection
16 Mar 2015ViiV Healthcare announces the approval in Japan of Triumeq® (dolutegravir, abacavir and lamivudine), a new single-pill regimen for the treatment of HIV infection -
ViiV Healthcare Announces $10 Million Initiative to Accelerate Response to HIV/AIDS Among Black Gay and Bisexual Men
04 Feb 2015ViiV Healthcare Announces $10 Million Initiative to Accelerate Response to HIV/AIDS Among Black Gay and Bisexual Men -
ViiV Healthcare announces regulatory submission in Japan for single-pill regimen combining dolutegravir, abacavir and lamivudine for the treatment of HIV
15 Dec 2014ViiV Healthcare announces regulatory submission in Japan for single-pill regimen combining dolutegravir, abacavir and lamivudine for the treatment of HIV -
Mylan's tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and CHAI
04 Dec 2014Mylan's tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and CHAI -
ViiV Healthcare announces new grants in support of ending mother to child transmission of HIV
27 Nov 2014ViiV Healthcare announces new grants in support of ending mother to child transmission of HIV -
GSK ranked top of the 2014 Access to Medicines (ATM) Index for the fourth consecutive time
18 Nov 2014GSK ranked top of the 2014 Access to Medicines (ATM) Index for the fourth consecutive time -
ViiV Healthcare Expands Program to Reduce HIV Disparities in Southern US
20 Oct 2014ViiV Healthcare Expands Program to Reduce HIV Disparities in Southern US -
ViiV Healthcare receives FDA approval for Triumeq
22 Aug 2014ViiV Healthcare receives FDA approval for Triumeq -
ViiV Healthcare presents phase III data comparing once-daily maraviroc
22 Jul 2014ViiV Healthcare presents phase III data comparing once-daily maraviroc -
ViiV Healthcare announces new collaboration with Janssen
12 Jun 2014ViiV Healthcare announces new collaboration with Janssen -
ViiV Healthcare announces new initiatives to improve access to dolutegravir: licence to the Medicines Patent Pool
01 Apr 2014ViiV Healthcare announces new initiatives to improve access to dolutegravir: licence to the Medicines Patent Pool -
ViiV Healthcare Announces Next Round of the Positive Action Southern Initiative to Support Linkages to HIV/AIDS Care and Treatment Adherence
19 Mar 2014ViiV Healthcare Announces Next Round of the Positive Action Southern Initiative to Support Linkages to HIV/AIDS Care and Treatment Adherence -
ViiV Healthcare’s new HIV medicine Tivicay™ (dolutegravir) is approved in Europe
21 Jan 2014ViiV Healthcare today announced that the European Commission has approved TivicayTM (dolutegravir), an integrase inhibitor, for use in combination with other anti-retroviral medicinal products for the treatment of HIV infected adults and adolescents above 12 years of age. -
ViiV Healthcare to Make Available Anonymised Patient-Level Data from its Clinical Trials
02 Jan 2014ViiV Healthcare to Make Available Anonymised Patient-Level Data from its Clinical Trials -
Update on patent ruling on ViiV Healthcare’s Epzicom® and Trizivir®
17 Dec 2013GSK and ViiV Healthcare confirmed today that the US District Court for the District of Delaware upheld the validity of a patent covering the double combination of lamivudine and abacavir (Epzicom®) and the triple combination of lamivudine, abacavir and zidovudine (Trizivir®). -
ViiV Healthcare commits £3.4M in Positive Action for Children Fund grants for programmes focused on prevention of mother-to-child transmission of HIV
10 Dec 2013Latest round of Positive Action for Children Fund grants brings total funding for programmes that empower women and children to £20 million to date. -
ViiV Healthcare announces European regulatory submission for single-tablet regimen
25 Oct 2013ViiV Healthcare announces European regulatory submission for single-tablet regimen -
ViiV Healthcare announces US regulatory submission for a single-tablet regimen combining dolutegravir with abacavir and lamivudine for people living with HIV
22 Oct 2013ViiV Healthcare announces US regulatory submission for a single-tablet regimen combining dolutegravir with abacavir and lamivudine for people living with HIV -
ViiV Healthcare Presents Positive Data from Phase IIIb/IV Study of Dolutegravir vs Darunavir in Treatment-Naïve Adults with HIV-1
12 Sep 2013ViiV Healthcare Presents Positive Data from Phase IIIb/IV Study of Dolutegravir vs Darunavir in Treatment-Naïve Adults with HIV-1 -
ViiV Healthcare Expands HIV/AIDS Community Support in Hard-Hit Southern US
04 Sep 2013ViiV Healthcare Expands HIV/AIDS Community Support in Hard-Hit Southern US -
ViiV Healthcare announces US approval of Tivicay® (dolutegravir) for the treatment of HIV-1
13 Aug 2013ViiV Healthcare announces US approval of Tivicay® (dolutegravir) for the treatment of HIV-1 -
ViiV Healthcare presents data from Phase III study of dolutegravir vs raltegravir in treatment-experienced adults with HIV-1
06 Mar 2013ViiV Healthcare presents 24-week interim results from Phase III SAILING study of dolutegravir -
ViiV Healthcare announces a voluntary licence agreement with the Medicines Patent Pool to increase access to HIV medicines for children
27 Feb 2013Medicines Patent Pool, voluntary licence, access, dolutegravir, abacavir -
ViiV Healthcare announces FDA priority review designation for dolutegravir as a potential treatment for HIV infection
15 Feb 2013dolutegravir, priority review, FDA -
ViiV Healthcare expands Positive Action Southern Initiative to fight HIV/AIDS and support community action
04 Feb 2013Positive Action Southern Initiative community action -
ViiV Healthcare announces regulatory submissions for dolutegravir in the EU, US and Canada
17 Dec 2012ViiV Healthcare announces regulatory submissions for dolutegravir in the EU, US and Canada -
ViiV Healthcare presents phase III data from VIKING-3 study of dolutegravir in HIV-1 infected integrase inhibitor-resistant adults
13 Nov 2012ViiV Healthcare presents phase III data from VIKING-3 study of dolutegravir in HIV-1 infected integrase inhibitor-resistant adults -
ViiV Healthcare commits nearly £4M in Positive Action for Children Fund grants for programmes focused on alleviating burden of HIV on women and children
08 Nov 2012ViiV Healthcare commits nearly £4M in Positive Action for Children Fund grants for programmes focused on alleviating burden of HIV on women and children -
Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio
28 Oct 2012Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio -
Shionogi-ViiV Healthcare announces completion of initial clinical registration package for dolutegravir in HIV
04 Oct 2012complete clinical registration package for dolutegravir -
ViiV Healthcare Expands Support for HIV Prevention and Education in Hard-Hit US Region
31 Jul 2012ViiV Healthcare Expands Support for HIV Prevention and Education in Hard-Hit US Region -
Once-Daily Dolutegravir is Non-Inferior to Twice-Daily Raltegravir in Treatment-Naïve Adults with HIV-1
26 Jul 2012Once-Daily Dolutegravir is Non-Inferior to Twice-Daily Raltegravir in Treatment-Naïve Adults with HIV-1 -
ViiV Healthcare Expands Commitment to Addressing Gaps in Paediatric HIV Research, Care and Treatment
18 Jul 2012ViiV Healthcare Expands Commitment to Addressing Gaps in Paediatric HIV Research, Care and Treatment -
Shionogi – ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV
11 Jul 2012Shionogi – ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV -
Shionogi – ViiV Healthcare announces initial data from Pivotal Phase III study of dolutegravir in HIV
02 Apr 2012Shionogi – ViiV Healthcare announces initial data from Pivotal Phase III study of dolutegravir in HIV -
Media Alert: ViiV Healthcare’s Positive Action for Children Fund announces 16 new grantees for the year 2011/2012
13 Oct 2011Media Alert: ViiV Healthcare’s Positive Action for Children Fund announces 16 new grantees for the year 2011/2012 -
ViiV Healthcare starts phase III programme of Celsentri/Selzentry versus Truvada in combination with a protease inhibitor in people living with HIV
11 Oct 2011ViiV Healthcare starts phase III programme of Celsentri/Selzentry versus Truvada in combination with a protease inhibitor in people living with HIV -
ViiV Healthcare Reaffirms Commitment to US Regions Hardest Hit by HIV/AIDS
26 Sep 2011ViiV Healthcare Reaffirms Commitment to US Regions Hardest Hit by HIV/AIDS -
Regulatory Update – Celsentri/Selzentry® (maraviroc)
20 Sep 2011Regulatory Update – Celsentri/Selzentry® (maraviroc) -
ViiV Healthcare Awards Small Grants from Positive Action for Children Fund to 82 Charitable Organisations Globally
20 Jun 2011ViiV Healthcare Awards Small Grants from Positive Action for Children Fund to 82 Charitable Organisations Globally -
ViiV Healthcare Expands Positive Action US Southern Initiative to Fight HIV/AIDS in Hard-hit Region
04 Apr 2011ViiV Healthcare Expands Positive Action US Southern Initiative to Fight HIV/AIDS in Hard-hit Region -
Regulatory Update – Celsentri/Selzentry® (maraviroc)
04 Mar 2011Regulatory Update – Celsentri/Selzentry® (maraviroc) -
David Redfern appointed as Chairman of the Board for ViiV Healthcare
25 Feb 2011David Redfern appointed as Chairman of the Board for ViiV Healthcare -
Positive Action and Vida Digna - further information
14 Feb 2011Positive Action and Vida Digna - further information -
ViiV Healthcare’s Positive Action and the International HIV/AIDS Alliance Tackle HIV Stigma in Six Central American Countries
14 Feb 2011ViiV Healthcare’s Positive Action and the International HIV/AIDS Alliance Tackle HIV Stigma in Six Central American Countries -
Global Agenda for Elimination of Mother to Child Transmission of HIV: Positive Action for Children Fund Calls for Proposals to Fill the Gaps
15 Dec 2010Global Agenda for Elimination of Mother to Child Transmission of HIV: Positive Action for Children Fund Calls for Proposals to Fill the Gaps -
Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor
21 Oct 2010Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor -
ViiV Healthcare acts to improve access to HIV Medicines in United States for those most in need
12 Oct 2010ViiV Healthcare acts to improve access to HIV Medicines in United States for those most in need -
ViiV Healthcare Awards Southern Initiative Grants to Reduce HIV Disparities Among African Americans and Latinos
09 Sep 2010Southern Initiative, Positive Action, Grants -
Shionogi - ViiV Healthcare Announces Commitment to Phase III Development Programme for Investigational Once-Daily HIV Integrase Inhibitor
21 Jul 2010Shionogi - ViiV Healthcare Announces Commitment to Phase III Development Programme for Investigational Once-Daily HIV Integrase Inhibitor -
Positive Phase IIb Data on Investigational Once-Daily Integrase Inhibitor, 572, presented at International AIDS Conference
21 Jul 2010Positive Phase IIb Data on Investigational Once-Daily Integrase Inhibitor, 572, presented at International AIDS Conference -
ViiV Healthcare Announces Positive Action US Southern Initiative, an Innovative Community Support Program to Fight HIV/AIDS
06 Jul 2010ViiV Healthcare Announces Positive Action US Southern Initiative, an Innovative Community Support Program to Fight HIV/AIDS -
ViiV Healthcare Awards Grants from the Positive Action for Children Fund of £3.6m
30 Jun 2010ViiV Healthcare Awards Grants from the Positive Action for Children Fund of ?3.6m -
ViiV Healthcare and amfAR Partner to Optimize HIV Treatment for Infants and Children in Asia
17 Jun 2010ViiV Healthcare and amfAR Partner to Optimize HIV Treatment for Infants and Children in Asia -
ViiV Healthcare and Elizabeth Glaser Paediatric AIDS Foundation Partner to Expedite Access to ARV Treatment for Infants and Children
07 Jun 2010ViiV Healthcare and Elizabeth Glaser Paediatric AIDS Foundation Partner to Expedite Access to ARV Treatment for Infants and Children -
ViiV Healthcare Calls for Initial Grant Proposals to the Positive Action for Children Fund
22 Mar 2010ViiV Healthcare Calls for Initial Grant Proposals to the Positive Action for Children Fund -
FDA Approves Expanded Use of Selzentry® for Appropriate Patients Starting HIV Antiretroviral Therapy for the First Time
20 Nov 2009FDA Approves Expanded Use of Selzentry® for Appropriate Patients Starting HIV Antiretroviral Therapy for the First Time -
GlaxoSmithKline and Pfizer announce innovative agreement to create a new world-leading, specialist HIV company
16 Apr 2009GlaxoSmithKline and Pfizer announce innovative agreement to create a new world-leading, specialist HIV company
These press releases and news updates are intended for media and investors only
-
Our response to the situation in Ukraine
22 May 2023 -
ViiV Healthcare PatientView 2022-2023 survey results
28 Apr 2023ViiV Healthcare is ranked number one for the tenth consecutive year in PatientView’s Corporate Reputation of Pharma – from the Patient Perspective 2022 - 2023 survey -
Update on ViiV’s response to COVID-19
21 Apr 2020 -
COVID-19 Guidance to Investigators
27 Mar 2020 -
ViiV’s position on COVID-19 outbreak
17 Mar 2020
Media contacts
Media contact details for our global headquarters and USA. For press contacts in our local operating companies please visit our country websites.
In you have a media query please use our Contact our team form here.
Global Press Office
Rachel Jaikaran
Head of Global Communications ViiV Healthcare
Tel: +44 7909 00240
US Press Office
Audrey Abernathy
Head of ViiV US External Affairs & Communications
Tel: +1 919 605 4521
NP-GBL-HVX-COCO-220024 November 2021.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. By reporting side effects, you can help provide more information on the safety of this medicine.
If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.